vs

Side-by-side financial comparison of Navitas Semiconductor Corp (NVTS) and Avidity Biosciences, Inc. (RNA). Click either name above to swap in a different company.

Avidity Biosciences, Inc. is the larger business by last-quarter revenue ($12.5M vs $7.3M, roughly 1.7× Navitas Semiconductor Corp). Navitas Semiconductor Corp runs the higher net margin — -436.1% vs -1398.3%, a 962.3% gap on every dollar of revenue. On growth, Avidity Biosciences, Inc. posted the faster year-over-year revenue change (434.0% vs -59.4%). Navitas Semiconductor Corp produced more free cash flow last quarter ($-8.2M vs $-156.9M). Over the past eight quarters, Avidity Biosciences, Inc.'s revenue compounded faster (138.5% CAGR vs -43.9%).

Navitas Semiconductor Corp is a leading global semiconductor firm specializing in gallium nitride (GaN) power integrated circuits. Its high-efficiency, compact power solutions serve consumer electronics, electric vehicles, renewable energy, and industrial sectors, with clients spanning North America, Asia, and Europe.

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

NVTS vs RNA — Head-to-Head

Bigger by revenue
RNA
RNA
1.7× larger
RNA
$12.5M
$7.3M
NVTS
Growing faster (revenue YoY)
RNA
RNA
+493.4% gap
RNA
434.0%
-59.4%
NVTS
Higher net margin
NVTS
NVTS
962.3% more per $
NVTS
-436.1%
-1398.3%
RNA
More free cash flow
NVTS
NVTS
$148.7M more FCF
NVTS
$-8.2M
$-156.9M
RNA
Faster 2-yr revenue CAGR
RNA
RNA
Annualised
RNA
138.5%
-43.9%
NVTS

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
NVTS
NVTS
RNA
RNA
Revenue
$7.3M
$12.5M
Net Profit
$-31.8M
$-174.4M
Gross Margin
38.1%
Operating Margin
-567.3%
-1513.5%
Net Margin
-436.1%
-1398.3%
Revenue YoY
-59.4%
434.0%
Net Profit YoY
20.2%
-117.0%
EPS (diluted)
$-0.14
$-1.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
NVTS
NVTS
RNA
RNA
Q4 25
$7.3M
Q3 25
$10.1M
$12.5M
Q2 25
$14.5M
$3.8M
Q1 25
$14.0M
$1.6M
Q4 24
$18.0M
$3.0M
Q3 24
$21.7M
$2.3M
Q2 24
$20.5M
$2.0M
Q1 24
$23.2M
$3.5M
Net Profit
NVTS
NVTS
RNA
RNA
Q4 25
$-31.8M
Q3 25
$-19.2M
$-174.4M
Q2 25
$-49.1M
$-157.3M
Q1 25
$-16.8M
$-115.8M
Q4 24
$-39.9M
$-102.3M
Q3 24
$-18.7M
$-80.4M
Q2 24
$-22.3M
$-70.8M
Q1 24
$-3.7M
$-68.9M
Gross Margin
NVTS
NVTS
RNA
RNA
Q4 25
38.1%
Q3 25
37.9%
Q2 25
16.1%
Q1 25
37.9%
Q4 24
12.4%
Q3 24
39.7%
Q2 24
39.0%
Q1 24
41.1%
Operating Margin
NVTS
NVTS
RNA
RNA
Q4 25
-567.3%
Q3 25
-192.0%
-1513.5%
Q2 25
-149.4%
-4448.7%
Q1 25
-180.5%
-8360.9%
Q4 24
-216.9%
-4069.6%
Q3 24
-133.6%
-4200.9%
Q2 24
-152.1%
-4040.4%
Q1 24
-136.2%
-2178.6%
Net Margin
NVTS
NVTS
RNA
RNA
Q4 25
-436.1%
Q3 25
-190.2%
-1398.3%
Q2 25
-338.7%
-4089.3%
Q1 25
-120.1%
-7360.0%
Q4 24
-221.7%
-3439.5%
Q3 24
-86.4%
-3441.7%
Q2 24
-109.1%
-3461.8%
Q1 24
-15.9%
-1943.4%
EPS (diluted)
NVTS
NVTS
RNA
RNA
Q4 25
$-0.14
Q3 25
$-0.09
$-1.27
Q2 25
$-0.25
$-1.21
Q1 25
$-0.09
$-0.90
Q4 24
$-0.22
$-0.80
Q3 24
$-0.10
$-0.65
Q2 24
$-0.12
$-0.65
Q1 24
$-0.02
$-0.79

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
NVTS
NVTS
RNA
RNA
Cash + ST InvestmentsLiquidity on hand
$236.9M
$350.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$443.7M
$1.9B
Total Assets
$500.5M
$2.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
NVTS
NVTS
RNA
RNA
Q4 25
$236.9M
Q3 25
$150.6M
$350.2M
Q2 25
$161.2M
$243.9M
Q1 25
$75.1M
$254.2M
Q4 24
$86.7M
$219.9M
Q3 24
$98.3M
$370.2M
Q2 24
$111.7M
$575.8M
Q1 24
$128.9M
$471.4M
Stockholders' Equity
NVTS
NVTS
RNA
RNA
Q4 25
$443.7M
Q3 25
$371.0M
$1.9B
Q2 25
$388.9M
$1.2B
Q1 25
$341.8M
$1.3B
Q4 24
$348.0M
$1.4B
Q3 24
$380.8M
$1.5B
Q2 24
$388.1M
$1.2B
Q1 24
$397.9M
$830.9M
Total Assets
NVTS
NVTS
RNA
RNA
Q4 25
$500.5M
Q3 25
$430.2M
$2.1B
Q2 25
$449.4M
$1.4B
Q1 25
$370.8M
$1.5B
Q4 24
$390.0M
$1.6B
Q3 24
$419.4M
$1.6B
Q2 24
$439.1M
$1.3B
Q1 24
$467.9M
$951.5M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
NVTS
NVTS
RNA
RNA
Operating Cash FlowLast quarter
$-8.1M
$-156.2M
Free Cash FlowOCF − Capex
$-8.2M
$-156.9M
FCF MarginFCF / Revenue
-111.8%
-1257.6%
Capex IntensityCapex / Revenue
0.7%
5.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-44.4M
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
NVTS
NVTS
RNA
RNA
Q4 25
$-8.1M
Q3 25
$-10.0M
$-156.2M
Q2 25
$-11.2M
$-199.7M
Q1 25
$-13.5M
$-124.8M
Q4 24
$-10.2M
$-99.9M
Q3 24
$-13.7M
$-65.6M
Q2 24
$-15.1M
$-65.0M
Q1 24
$-19.8M
$-70.4M
Free Cash Flow
NVTS
NVTS
RNA
RNA
Q4 25
$-8.2M
Q3 25
$-10.7M
$-156.9M
Q2 25
$-11.9M
$-203.0M
Q1 25
$-13.6M
$-128.6M
Q4 24
$-10.8M
$-103.8M
Q3 24
$-14.3M
$-67.3M
Q2 24
$-17.9M
$-65.5M
Q1 24
$-22.7M
$-71.3M
FCF Margin
NVTS
NVTS
RNA
RNA
Q4 25
-111.8%
Q3 25
-106.1%
-1257.6%
Q2 25
-82.2%
-5277.1%
Q1 25
-96.8%
-8174.3%
Q4 24
-59.8%
-3491.0%
Q3 24
-65.9%
-2881.8%
Q2 24
-87.3%
-3204.6%
Q1 24
-97.9%
-2012.3%
Capex Intensity
NVTS
NVTS
RNA
RNA
Q4 25
0.7%
Q3 25
7.0%
5.7%
Q2 25
4.7%
86.9%
Q1 25
0.3%
238.6%
Q4 24
3.1%
131.7%
Q3 24
2.6%
72.9%
Q2 24
13.4%
26.0%
Q1 24
12.5%
25.8%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons